ABSTRACT
Asthma is the most common chronic childhood condition and is a risk factor for severe respiratory viral infections. Thus, early during the coronavirus disease 2019 (COVID-19) pandemic there was concern that children with asthma would be at risk for severe COVID-19 illness and that asthma control could worsen as a result of the pandemic. This article seeks to summarize what was learned in the early stages of the pandemic about the impact of COVID-19 on children with asthma. We review evidence from several studies that demonstrated a significant decline in asthma morbidity in the first year of the pandemic. Additionally, we describe several potential mechanisms that may explain the reduced frequency in childhood asthma exacerbations as well as review lessons learned for future management of childhood asthma. While the COVID-19 pandemic initially brought uncertainty, it soon became clear that the pandemic had several positive effects for children with asthma. Now we can apply the lessons that were learned during the pandemic to re-examine asthma care practices as well as advocate for best approaches for asthma management.
ABSTRACT
Aim. The study is aimed at investigating the incidence of lung cancer (LC) at the population level with the analysis of key analytical indicators in the context of coronavirus. Materials and methods. We have used data from the IARC, statistical reference books of P.A. Herzen Moscow Research Oncological Institute, data from N.N. Petrov NMRC of Oncol¬ogy, and the database of the Population Cancer Registry of St. Petersburg (DB PCR St. Petersburg) for the current study. Results. The study has established a steady decline in the incidence of LC among the male population in the worldwide, in Russia and in St. Petersburg. Among the female population, a significant increase in the incidence has been revealed. On the basis of the database PCR St. Petersburg, the patterns of age-sex indicators of the incidence of LC have been analyzed. It has been established that the largest number of cases is registered in the age group of patients over 70 years old, here the largest losses due to coronavirus have also been identified. An increase in the proportion of early stages of the disease has been noted. The accounting reliability index decreased from 2000 to 2019, with the exception of 2017. Comparison of yearly lethality in the DB PCR St. Petersburg showed a signifi¬cant difference in the data. The detailed localization structure of LC has been studied, where it has been found out that the first place is occupied by cancer of the upper lobe, bronchi or lung, although over 19 years of observation, a decrease in the proportion of this localization in the total volume of C34 has been noted. The proportion of patients with LC without histological verification has decreased. The influence of the smoking factor on the increased risk of LC has been studied.
ABSTRACT
The increasing size and density of the human population is leading to an increasing risk of infectious diseases that threaten to spread yet another pandemics. The widespread use of vaccination has reduced morbidity and mortality associated with viral infections and in some cases eradicated the virus from the population entirely. Regrettably, some virus species retain the ability to mutate rapidly and thus evade the vaccine-induced immune response. New antiviral drugs are therefore needed for the treatment and prevention of viral diseases. Modern research into the structures and properties of viral proteases, which are of key importance in the life cycle of viruses, makes it possible, in our opinion, to turn these enzymes into promising targets for the development of effective viral disease control methods.
ABSTRACT
Introduction: Kidney transplant (KT) recipients have a high risk for adverse outcomes from infections, such as COVID- 19. Methods: We have retrospectively reviewed all KT recipients with documented COVID-19 between March 1, 2020, and March 15, 2021, and analyzed patients' characteristics, clinical course, treatment, and outcomes. Results: We identified 123 patients, 72% were male, with a mean age of 54.5±13.0 years. Twenty percent were asymptomatic, 7% had a nosocomial transmission, and 36% of the remainder required hospitalization. Almost all admitted patients received oxygen, 30% required invasive mechanical ventilation (IMV), more than a half had acute kidney injury, with 10% requiring dialysis, and 20% died. Incidence was comparable to that of the Portuguese population, but the mortality rate was almost four times higher (SMR of 3.768 (95% CI:1.723-7.154). Higher body mass index (OR 1.275, P=0.001), lower baseline graft function (OR 0.968, P=0.015), and nosocomial transmission (OR 13.836, P=0.019) were associated with oxygen demand, whereas female gender (OR 3.801, P=0.031) and lower baseline kidney graft function (OR 0.955, P=0.005), but not body mass index, were associated with IMV and/or death. Conclusion: Mortality rate in KT patients was higher than in the general population and lower baseline kidney function was the most consistent marker for adverse outcomes.
ABSTRACT
Morbidity surveys in certain regions during the COVID-19 pandemic have established that the infection spreads in a wave-like manner characterised with peaks and troughs in incidence. According to the analysis of COVID-19 epidemic development in Russia, surges in COVID-19 infections are mainly driven by seasonal factors, insufficient herd immunity, and emerging SARS-CoV-2 variants with increased transmissibility. The aim of the study was to analyse environmental, biological and social factors contributing to new rises in COVID-19 cases in Russia. The study covers the global epidemiological situation as of mid-2022 and the role of environmental, biological, and social factors in the spread of COVID-19 in the Russian Federation. The results suggest that new highly contagious SARS-CoV-2 variants and seasonality are the principal factors driving new rises in morbidity. The authors assume that the sixth and the seventh COVID-19 waves in Russia will be in line with the best case scenario, which predicts the spread of a SARS-CoV-2 variant with increased transmissibility and reduced virulence.
ABSTRACT
Background and Objectives: Guidelines recommend deferral of elective surgery after COVID-19. Delays in cancer surgeries may affect outcomes. We examined perioperative outcomes of elective cancer surgery in COVID-19 survivors. The primary objective was 30-day all-cause postoperative mortality. The secondary objectives were 30-day morbidity, and its association with COVID-19 severity, and duration between COVID-19 and surgery. Methods: We collected data on age, gender, comorbidities, COVID-19 severity, preoperative investigations, surgery performed, and intra and postoperative outcomes in COVID-19 survivors who underwent elective cancer surgery at a tertiary-referral cancer center. Results: Three hundred and forty-eight COVID-19 survivors presented for elective cancer surgery. Of these, 332/348 (95%) patients had mild COVID-19 and 311 (89%) patients underwent surgery. Among patients with repeat investigations, computerized tomography scan of the thorax showed the maximum new abnormalities (30/157, 19%). The 30-day all-cause mortality was 0.03% (1/311) and 30-day morbidity was 17% (54/311). On multivariable analysis, moderate versus mild COVID-19 (odds ratio [OR]: 1.95;95% confidence interval [CI]: 0.52–7.30;p = 0.32) and surgery within 7 weeks of COVID-19 (OR: 0.61;95% CI: 0.33–1.11;p = 0.10) were not associated with postoperative morbidity. Conclusions: In patients who recover from mild to moderate COVID-19, elective cancer surgery can proceed safely even within 7 weeks. Additional preoperative tests may not be indicated in these patients. © 2022 Wiley Periodicals LLC.
ABSTRACT
Case Report: Pulmonary embolism (PE) is a form of venous thromboembolism (VTE) which causes an obstruction of the pulmonary vasculature. Massive PE can be a fatal, accounting for over 100,000 death/year in the US. Incidence of PEs is increased in COVID-19 infections, due to a hypercoagulable state resulting from endothelial injury, stasis and increase in prothrombic factors. We report a case of a 48-year-old male with past medical history of mild form of COVID-19 infection approx. 6 months back. He was brought to the ED after cardiac arrest resuscitated in the ambulance. 3 days prior to the cardiac arrest he presented in the ED for nonspecific upper respiratory tract symptoms, for which he received symptomatic treatment. During that visit all the workup was negative except for sinus tachycardia. The cause of patient's cardiac arrest was found to be massive bilateral PE leading to right ventricular strain, shock, and HFrEF (20%). Our patient received thrombolytic, ECMO, thrombectomy, anticoagulation, and required complex treatment for several complication during hospitalization. Was eventually discharged home recovered. COVID-19 pandemic has been one of the worst in human history, causing millions of deaths. Symptoms of COVID-19 infection vary from mild upper respiratory disease to respiratory failure or severe VTEs. Multiple studies including a large national study in Sweden reported COVID-19 being an independent risk factor for VTEs, risk extending up to 180 days after COVID-19 infection, especially in unvaccinated population as seen in our patient. New variants of SARS-Cov 2 pose a challenge to control the spread of COVID-19 infection. As more studies support COVID-19 infection association with hypercoagulability status, varied nonspecific symptomology of PE remains a diagnostic and treatment dilemma. Physicians should have low threshold for investigating PEs in patients with unexplained sinus tachycardia or non-specific respiratory distress, especially in an unvaccinated post-COVID-19 patient, including historical mild forms of infection. Many studies have arguably advocated "treatment to prevent thrombotic events” in post COVID- 19 infection, however, vaccination remains the corner stone to reduce morbidity and mortality associated with serious thrombotic events like massive PEs in patients exposed to COVID1-19.
ABSTRACT
Background: COVID-19 is an international public health emergency in the world. Objectives: The aim of the present study is to determine the geographic pattern and temporal trend of Coronavirus disease 2019 incidence, fatality, and recovery rates worldwide. Methods: The present ecological study is a mixed exploratory study. The study population included Patients with COVID-19, recov-ered individuals, and deaths from COVID-19 from October 1, 2019, until June 30, 2021, worldwide. Descriptive analysis included the calculation cumulative incidence rate (CIR), case fatality rate (CFR), and case recovery rate (CRR) of COVID-19. Global Moran's I and Anselin Local Moran's I tests were used for spatial analysis. The joinpoint regression analysis was used to examine the time trend by ArcGIS, Joinpoint, and SPSS software. Results: The average cumulative incidence rate was 1077 in 106 individuals;also, the average case recovery rate and average case fatality rate were %72.81 and %3.21, respectively. Global Moran's I index measured for CIR was 0.159. The results of Anselin's local Moran's I, high-high cluster, consists of some countries in South America and in southern and Western Europe and central and western Asia. The temporal trend of changes in the incidence rate and CRR of COVID-19 were incremental, and the average annual percentage change from October 2019 to June 2021 increased by 44.4% and 3.2%, respectively (P < 0.001), but CFR decreased by-0.3% and was not significant (P > 0.05). Conclusions: As regards the specific spatial pattern of fatality and recovery rate of COVID-19, it seems essential to consider spatial conditions and environmental factors which are related to the incidence and fatality of COVID-19 in different regions, as well as the necessity of upgrading the care system in high-risk areas, in order to have better management and control of the pandemic and optimal function in early diagnosis, proper treatment, and high vaccination coverage. © 2023, Author(s).
ABSTRACT
Objective: To determine risk factors associated with development of AKI with regards to mortality rate among covid-19 patients taking in consideration risk factors such as age, sex and chronic diseases like diabetics considering renal function to outcome. Design and method: This is a retrospective cohort study using de-identified data retrieved from clinical records of patients from two COVID 19 isolation centers. Medical history, demographic data, symptoms, disease complications and laboratory investigations were extracted from clinical records of 406 confirmed COVID 19 hospitalized patients in the period between Feb 2020 and July 2021. Continuous variables were presented as means ± standard deviation (SD) while categorical variables were presented as percent proportions. Logistic regression was used to determine risk factors associated with development of AKI with regards to mortality factors rate among covid 19 hypertensive patients. Result: Out of 406 hospitalized COVID-19 patients, 59.6% had a history of hypertension. Logistic regression was used to analyze risk factors associated with AKI among hypertensive and non hypertensive patients of covid-19. Age factor is highly significant factor for development of AKI for hypertensive (odd ratio [OR]: 4.89, 95% confidence interval [CI]: (1.93-1.36, P = 0.001) and non-hypertensive patients (odd ratio [OR]: 4.73, 95% confidence interval [CI]: (1.58-4.18, P = 0.001). Urea (odd ratio [OR]: 3.06, 95% confidence interval [CI]: (1.63-5.76, P = 0.001), creatinine (odd ratio [OR]: 3.39, 95% confidence interval [CI]: (1.82-6.32, P > 0.001) and potassium[K] (odd ratio [OR]: 2.17, 95% confidence interval [CI]: (2.23-3.83, P = 0.035) are highly significantly increased for hypertensive covid- 19 patients, whereas urea, creatinine and K are not significantly changed for non-hypertensive covid-19 patients Gender and morbidity factor (diabetes mellitus) has no significant effect for AKI development for hypertensive and non-hypertensive covid-19 patients. AKI is considered as a risk factor death among COVID-19 patients (OR:284, CI:1.56-5.15, p = 0.001). Conclusion: The present study indicates that 71% of patients with AKI are hypertensive. The results also highlight the alarming high incidents of hypertension in the studied population. On conclusion hypertension is considered as highly morbidity factor for development of AKI.
ABSTRACT
Inequalities in health care exist in many countries in the world. In 2008 the then UK Secretary of State for Health commissioned the Marmot review, ‘Fair Society, Healthy Lives', to propose strategies to address health inequalities in the UK. Most of Marmot's proposals were not acted upon and in 2020, 10 years after the initial recommendations were published, Marmot found that there had been no improvement and some things were worse. In diabetes care inequalities are widespread, impacting on prevention, treatment, access to technology, screening for complications, risk of complications, morbidity and mortality. Ethnicity is a major risk factor, starkly demonstrated by the increased COVID-19 related mortality in people from minority ethnic groups with diabetes. Disadvantaged groups include, but are not limited to, those with social deprivation, intellectual and physical disabilities and severe mental illness. The decision to shelve the long-awaited white paper on tackling health inequalities, taken recently by the last Secretary of State for Health amid protests from a coalition of medical organisations, makes it unlikely that the government will take the actions proposed by Marmot. In the absence of a national strategy, responsibility to recognise and address inequalities in diabetes care falls on health care professionals, in teams and as individuals. Copyright © 2023 John Wiley & Sons.
ABSTRACT
Introduction. It is important for SARS-CoV2 vaccine providers, vaccine recipients, and those not yet vaccinated to be well informed about vaccine side effects. We sought to estimate the risk of post-vaccination VTE to meet this need. Methods. We conducted a retrospective cohort study to quantify excess VTE risk associated with SARS-CoV2 vaccination in US veterans age 45 and older using data from the Department of Veterans Affairs (VA) National Surveillance Tool. The vaccinated cohort received at least one dose of a SARS-CoV-2 vaccine at least 60 days prior to 3/06/22 (N=855,686). The control group were those not vaccinated (N=321,676). All patients were COVID-19 tested at least once before vaccination with a negative test. The main outcome was VTE documented by ICD10-CM codes. Results. Vaccinated persons had a VTE rate of 1.3755 (CI: 1.3752-1.3758) per thousand, which was 0.1 percent over the baseline rate of 1.3741 (CI: 1.3738-1.3744) per thousand in the unvaccinated patients, or 1.4 excess cases per 1,000,000. All vaccine types showed a minimal increased rate of VTE (rate of VTE per 1000 was 1.3761 (CI: 1.3754-1.3768) for Janssen;1.3757 (CI: 1.3754-1.3761) for Pfizer and for Moderna the rate was 1.3757 (CI: 1.3748-1.3877)). The tiny differences in rates comparing either Janssen or Pfizer vaccine to Moderna were statistically significant (p<0.001). Adjusting for age, sex, BMI, 2-year Elixhauser score, and race, the vaccinated group had a minimally higher relative risk of VTE as compared to controls (1.0009927 CI: 1.007673-1.0012181;p<0.001) Conclusion. The results provide reassurance that there is only a trivial increased risk of VTE with the current U.S. SARS-COV2 vaccines used in veterans older than age 45. This risk is significantly less than VTE risk amongst hospitalized COVID-19 patients. The risk-benefit ratio favors vaccination, given the VTE rate, mortality and morbidity associated with COVID-19 infection.
ABSTRACT
Aim: In light of the severe acute respiratory syndrome by a coronavirus-2 (SARS-CoV-2) pandemic, it was proposed that a variety of complications have occurred in women during pregnancy, which has further extended to the fetus, causing higher rates of morbidity and mortality. The objective of this study was to identify the complications that arose due to the coronavirus and asses how it impacted the pregnancy, the fetus, and the neonate. Materials and methods: Our study was a descriptive and observational study, which investigated the various aspects, obstetric, fetal and neonatal outcomes, and the complications arising in mothers affected with by SARS-CoV-2 virus. All women who tested positive after 20 weeks of gestation were included in the study and their pregnancy was followed up till delivery, and neonatal outcomes were noted. Results: About 220 women infected with SARS-CoV-2 were studied and outcomes were illustrated. The mean age of the study population was 26.87 years [±4.96 Standard Deviation (SD)]. About 90% of the study population had a mild illness. The main obstetric outcomes noted were preterm labor, preeclampsia, eclampsia, intrauterine growth restriction (IUGR), and intrauterine fetal demise (IUD). Only 4.1% required a cesarean section for worsening conditions. Neonatal intensive care unit (ICU) admissions were also noted to be higher, with a possibility of vertical transmission in six babies. Conclusion: Severe acute respiratory syndrome by a coronavirus-2 can have serious implications and can pose a great risk in pregnancy if not caught and treated early. Therefore, it is vital to screen those at high risk for the virus to prevent severe complications from taking a toll on the mother and fetus. Clinical significance: By identifying the main complications occurring in pregnancy, we can prevent the same by anticipating and monitoring carefully, thereby reducing mortality and morbidity rates.
ABSTRACT
Background and objectives: COVID-19 is a life-threatening disease. Recognizing the main characteristics of the disease and its main complications will help future interventions, care, and management of health services since territorial and population diversities directly influence health outcomes. Our main objective is to describe the clinical characteristics, outcomes, and factors associated with mortality of patients with COVID-19 admitted to the intensive care unit of a public and tertiary hospital. Methods: Cohort study, conducted from March 1 to September 30, 2020. Poisson regression was performed to investigate the variables of hospital treatment as potential risk factors for in-hospital mortality. Results: Of the 283 eligible patients in this study, the hospital mortality rate was of 41.7% (n=118). The most common outcomes were acute respiratory distress syndrome, nosocomial infection, and septic shock. Factors independently associated with increased risk of death were age greater than 51 years old (RR=1.7, 95%CI=1.0-2.8), especially over 70 years old (RR=2.9, 95%CI=1.7-2.8), current smoker (RR=1.8, 95%CI=1.1-2.9), requiring the use of inotrope (RR=1.4, 95%CI=1.0-2.0), and presenting potassium greater than 5.0 mEq/l on admission (RR=1.3, 95%CI=1.0-1.7). Conclusion: Mortality was associated with older age, being a current smoker, inotrope use, and presenting potassium greater than 5.0 on hospital admission.
ABSTRACT
Hemorrhagic cholecystitis is a rare disorder associated with considerable morbidity and mortality. The clinical presentation of hemorrhagic cholecystitis is non-specific and imaging findings can be difficult to accurately interpret without a high level of suspicion. Most recent reports of hemorrhagic cholecystitis have been associated with concurrent therapeutic anticoagulation. Here, we report imaging findings of a case of acute, spontaneous hemorrhagic cholecystitis in a 67-year-old male patient admitted for hypoxic respiratory failure secondary to COVID-19 pneumonia. © 2022
ABSTRACT
COVID-19, caused by SARS-CoV-2, has rapidly progressed globally started from early days of 2020 and was disseminated to 187 countries and territories by April. As of May 3, 2020, COVID-19 has led to a total of 3,507,442 cases and 245,241 related deaths, globally. Turkey, was successful to delay the first COVID-19 case until March 10, yet, case numbers increased fast, reaching to the top 7th rank in the list of countries with the highest case numbers. It is fortunate that the case-fatality ratio was relatively low, with a somewhat stable course around 2.5%. Somewhat stable course of new case numbers, with an apparent decrease through the end of April led to onset of normalization attempts in the country. The future course of the pandemic will be mainly determined by compliance of the general public with personal hygiene, mask use and social distancing. Globally, COVID-19-related morbidity and mortality rates are lower among children than in adults. Underlying mechanisms for this difference has not been clarified, yet, may be linked to lower exposure rates among children, their immune response may be different and/or higher rates of asymptomatic cases may have lower admissions/testing among children. However, it is important to emphasize that children are prone to SARS-CoV-2, too and all relevant preventions should be ensured. This issue should also be considered in evaluating potential risk of infection transfer from asymptomatic youngsters to the elderly and/or to those with chronic diseases. Data on COVID-19-related case numbers and deaths in Turkey have not been published so far for children. This requires urgent consideration for related reporting and novel research activities on health burden of COVID-19 on Turkish children. Success in combating the COVID-19 pandemic requires concurrent efforts for clinical management of patients together with epidemiological studies of available national data and establishment of specific research to provide evidence for national and international preventive interventions. Learnings from this pandemic will provide direct evidence for management of future pandemics, and all related parties should be motivated to prepare detailed reporting of ongoing efforts and their outputs.
ABSTRACT
Currently, the disease caused by the new coronavirus (COVID-19) and the possibility of co-infection with SARS-CoV-2 and other pathogens in the current epidemic situation continues to be of particular interest. The review, based on the analysis of literature and own materials, outlines the features of the relationship between SARS-CoV-2 and pathogens of acute respiratory viral infections (ARVI). Particular attention is paid to the combined course of COVID-19 and influenza, a comparative characteristic of the severity of the clinical picture. An assessment of the epidemic situation against the backdrop of the COVID-19 pandemic in foreign countries and the Russian Federation (RF) revealed the presence of the phenomenon of SARS-CoV-2 interference with other viral respiratory agents, based on the facts of a sharp suppression of the circulation of influenza viruses, respiratory syncytial virus (RSV) and other ARVI pathogens during the period of active spread of pandemic coronavirus. The main epidemiological indicators of the course of coronavirus infection were compared and the contribution of various pathogens to the etiology of acute respiratory viral infections during the development of the second wave of COVID-19 in the RF was assessed. It was noted that the decrease in the number of new cases by 11.4 and deaths by 2.1 times due to COVID-19 at 6 and 13 weeks in 2022 occurred with unchanged laboratory detection of the influenza virus (0.8%) and an increase in the frequency detection of pathogens of other SARS. The results of observations showed that against the background of a decrease in the incidence of COVID-19, there was no increase in the proportion of diagnosed cases of infections caused by other pathogens, especially influenza. The results obtained confirm the need to ensure effective epidemiological surveillance and additional application of pathogen identification methods for monitoring various ARVI, which can significantly affect the approach to differential diagnosis, patient management tactics and the decision on appropriate preventive measures.
ABSTRACT
Introduction: A clinically significant variant of SARS-CoV-2 was identified in the UK in December 2020 and was designated VOC‐202012/01 (lineage B.1.1.7) on 14 December 2020. Our study aimed to evaluate the lineage B.1.1.7 prevalence over time and demographic, hematological, coagulation, inflammation characteristics in hospitalized patients with B.1.1.7 during February-March 2021. Materials and Methods: Between 5 February and 20 March 2021, 182 inpatients with B.1.1.7 were included in this study. Bio-Speedy, SARS-CoV-2 Double Gene RT-qPCR (Bioeksen, Ístanbul, Türkiye) kit was used to diagnose COVID-19. Cycle threshold< 27 samples were taken into mutation study with Bio-Speedy SARS-CoV-2 Variant Plus kit. Results: Of the 5187 SARS-CoV-2 positive cases, 2288 (69.65%) were evaluated as variant B.1.1.7 positive. Throughout the study, the case number's daily increase rate was 8.78% in SARS CoV-2, 13.16% in B.1.1.7;the case number's doubling time was calculated as 7.9 days in SARS CoV-2 and 5.27 days in B.1.1.7. In ICU patients, hemoglobin (p< 0.001), platelet (p= 0.034) and lymphocyte (p< 0.001) levels were lower but neutrophil (p= 0.025), monocyte/lymphocyte ratio (MLR) (p= 0.002), neutrophil/lymphocyte (NLR) (p< 0.001) ratio and D-dimer (p= 0.008) levels were dedected higher than non-ICU patients. Conclusion: Our study demonstrated that the infectiousness of B.1.1.7 was higher than previous variants and became the dominant SARS-CoV-2 in six weeks in our region. Therefore, urgent and decisive measures should be taken to minimize morbidity and mortality associated with COVID-19. In addition, our findings indicate that first hematologic markers of the patients can be an important biomarker for the prognosis of COVID-19 disease.
ABSTRACT
Emergency departments are on the front line in the management of Covid-19 cases. Emergency department personal need to be equipped with appropriate personal protective equipment and trained in its use. Pre-triage screening is necessary to prevent nosocomial infection. The clinical presentation of Covid-19 ranges from non-specific symptoms to acute respiratory distress syndrome. Personal in triage must maintain a high index of suspicion when evaluating all patients, but especially those with fever, cough, dyspnea, or signs of a respiratory illness. Healthcare workers who perform aerosol processing should be carefully. Even though morbidity and mortality are rare in pediatric population, clinicians should be aware that they may infect more vulnerable populations and social distance should be encouraged.
ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) caused significant mortality and mortality worldwide. There is limited information describing the outcomes of COVID-19 in cancer patients. Methods: We utilized the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (NIS) 2020 database to collect information on cancer patients hospitalized for COVID-19 in the United States. Using the International Classification of Diseases, 10th revision, Clinical Modification (ICD-10-CM) coding system, adult (≥18 years) patients with COVID-19 were identified. Adjusted analyses were performed to assess for mortality, morbidity, and resource utilization among cancer patients. Results: A total of 1,050,045 patients were included. Of them, 27,760 had underlying cancer. Cancer patients were older and had more comorbidities. The all-cause in-hospital mortality rate in cancer patients was 17.58% vs. 11% in non-cancer. After adjusted logistic regression, cancer patients had a 21% increase in the odds of all-cause in-hospital mortality compared with those without cancer (adjusted odds ratio (aOR) 1.21, 95%CI 1.12−1.31, p-value < 0.001). Additionally, an increased odds in acute respiratory failure rate was found (aOR 1.14, 95%CI 1.06−1.22, p-value < 0.001). However, no significant differences were found in the odds of septic shock, acute respiratory distress syndrome, and mechanical ventilation between the two groups. Additionally, no significant differences in the mean length of hospital stay and the total hospitalization charges between cancer and non-cancer patients. Conclusion: Cancer patients hospitalized for COVID-19 had increased odds of all-cause in hospital mortality and acute respiratory failure compared with non-cancer patients.